JP2014522840A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014522840A5 JP2014522840A5 JP2014519087A JP2014519087A JP2014522840A5 JP 2014522840 A5 JP2014522840 A5 JP 2014522840A5 JP 2014519087 A JP2014519087 A JP 2014519087A JP 2014519087 A JP2014519087 A JP 2014519087A JP 2014522840 A5 JP2014522840 A5 JP 2014522840A5
- Authority
- JP
- Japan
- Prior art keywords
- oil
- water emulsion
- immunogenic cationic
- immunogenic
- emulsion according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161505091P | 2011-07-06 | 2011-07-06 | |
| US61/505,091 | 2011-07-06 | ||
| US201261585639P | 2012-01-11 | 2012-01-11 | |
| US61/585,639 | 2012-01-11 | ||
| PCT/US2012/045840 WO2013006834A1 (en) | 2011-07-06 | 2012-07-06 | Oil-in-water emulsions that contain nucleic acids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016238363A Division JP2017057213A (ja) | 2011-07-06 | 2016-12-08 | 核酸を含む水中油型エマルジョン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014522840A JP2014522840A (ja) | 2014-09-08 |
| JP2014522840A5 true JP2014522840A5 (enExample) | 2015-08-27 |
| JP6059220B2 JP6059220B2 (ja) | 2017-01-18 |
Family
ID=46551895
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014519087A Expired - Fee Related JP6059220B2 (ja) | 2011-07-06 | 2012-07-06 | 核酸を含む水中油型エマルジョン |
| JP2016238363A Withdrawn JP2017057213A (ja) | 2011-07-06 | 2016-12-08 | 核酸を含む水中油型エマルジョン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016238363A Withdrawn JP2017057213A (ja) | 2011-07-06 | 2016-12-08 | 核酸を含む水中油型エマルジョン |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9655845B2 (enExample) |
| EP (2) | EP2729125B1 (enExample) |
| JP (2) | JP6059220B2 (enExample) |
| CN (1) | CN103781470A (enExample) |
| AU (2) | AU2012280901B2 (enExample) |
| CA (1) | CA2840913C (enExample) |
| ES (1) | ES2657547T3 (enExample) |
| MX (1) | MX350198B (enExample) |
| RU (1) | RU2606846C2 (enExample) |
| SG (1) | SG10201605512WA (enExample) |
| TR (1) | TR201802662T4 (enExample) |
| WO (1) | WO2013006834A1 (enExample) |
Families Citing this family (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10487332B2 (en) | 2010-07-06 | 2019-11-26 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
| PT3243526T (pt) | 2010-07-06 | 2020-03-04 | Glaxosmithkline Biologicals Sa | Distribuição de arn para despoletar múltiplas vias imunitárias |
| CN103153284B (zh) | 2010-07-06 | 2015-11-25 | 诺华股份有限公司 | 含有其pKa值有利于RNA递送的脂质的脂质体 |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| JP5911870B2 (ja) | 2010-08-31 | 2016-04-27 | ノバルティス アーゲー | 免疫原をコードするｒｎａの送達のためのｐｅｇ化リポソーム |
| EP2857499A1 (en) | 2010-10-01 | 2015-04-08 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| KR102266691B1 (ko) | 2010-10-11 | 2021-06-23 | 노파르티스 아게 | 항원 전달 플랫폼 |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| KR20220025112A (ko) | 2011-06-08 | 2022-03-03 | 샤이어 휴먼 지네틱 테라피즈 인크. | Mrna 전달을 위한 지질 나노입자 조성물 및 방법 |
| US9655845B2 (en) | 2011-07-06 | 2017-05-23 | Glaxosmithkline Biologicals, S.A. | Oil-in-water emulsions that contain nucleic acids |
| US9636410B2 (en) | 2011-07-06 | 2017-05-02 | Glaxosmithkline Biologicals Sa | Cationic oil-in-water emulsions |
| JP2014522842A (ja) * | 2011-07-06 | 2014-09-08 | ノバルティス アーゲー | 免疫原性組み合わせ組成物およびその使用 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9512456B2 (en) | 2012-08-14 | 2016-12-06 | Modernatx, Inc. | Enzymes and polymerases for the synthesis of RNA |
| FR2998899B1 (fr) * | 2012-11-30 | 2015-07-17 | Commissariat Energie Atomique | Methode de criblage a haut-debit pour l'identification de biomarqueurs, cibles therapeutiques ou d'agents therapeutiques |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| AU2014204826A1 (en) | 2013-01-10 | 2015-07-09 | Seqirus UK Limited | Influenza virus immunogenic compositions and uses thereof |
| US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| PL2970948T3 (pl) | 2013-03-15 | 2019-06-28 | Glaxosmithkline Biologicals Sa | Sposoby oczyszczania rna |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| US10842859B2 (en) | 2014-03-25 | 2020-11-24 | Yale University | Uses of parasite macrophage migration inhibitory factors |
| HRP20220070T1 (hr) | 2014-04-23 | 2022-04-01 | Modernatx, Inc. | Cjepiva nukleinske kiseline |
| EP2974739A1 (en) | 2014-07-15 | 2016-01-20 | Novartis AG | RSVF trimerization domains |
| MA40871A (fr) * | 2014-10-29 | 2017-09-05 | Novartis Ag | Expression directe d'anticorps |
| EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| MA42502A (fr) | 2015-07-21 | 2018-05-30 | Modernatx Inc | Vaccins contre une maladie infectieuse |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| HRP20220156T1 (hr) | 2015-09-17 | 2022-04-15 | Modernatx, Inc. | Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava |
| EP3359670B2 (en) | 2015-10-05 | 2024-02-14 | ModernaTX, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
| DE20164728T1 (de) | 2015-10-22 | 2021-09-30 | Modernatx, Inc. | Impfstoffe gegen atemwegsvirus |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| DK3386484T3 (da) | 2015-12-10 | 2022-07-04 | Modernatx Inc | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler |
| RS63051B1 (sr) | 2015-12-22 | 2022-04-29 | Modernatx Inc | Jedinjenja i kompozicije za intracelularnu isporuku agenasa |
| WO2017162266A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for versatile and efficient gene expression |
| WO2017162265A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
| WO2017208191A1 (en) | 2016-06-02 | 2017-12-07 | Glaxosmithkline Biologicals Sa | Zika viral antigen constructs |
| WO2018060288A1 (en) | 2016-09-29 | 2018-04-05 | Glaxosmithkline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
| GB201616904D0 (en) | 2016-10-05 | 2016-11-16 | Glaxosmithkline Biologicals Sa | Vaccine |
| EP3538067A1 (en) | 2016-11-08 | 2019-09-18 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| EP3541416A1 (en) | 2016-11-17 | 2019-09-25 | GlaxoSmithKline Biologicals SA | Zika viral antigen constructs |
| WO2018170322A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| RS63953B1 (sr) | 2017-03-15 | 2023-02-28 | Modernatx Inc | Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava |
| JP7332478B2 (ja) | 2017-03-15 | 2023-08-23 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子製剤 |
| US20200038499A1 (en) * | 2017-03-22 | 2020-02-06 | Modernatx, Inc. | Rna bacterial vaccines |
| RU2656216C1 (ru) * | 2017-03-24 | 2018-06-01 | Федеральное государственное бюджетное учреждение науки Институт биоорганической химии им. М.М. Шемякина и Ю.А. Овчинникова Российской академии наук | Способ ультравысокопроизводительного скрининга клеток или микроорганизмов и средство для ультравысокопроизводительного скрининга клеток или микроорганизмов |
| EP3638678B1 (en) | 2017-06-14 | 2025-12-03 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| AU2018285694B2 (en) | 2017-06-15 | 2025-04-10 | Access To Advanced Health Institute | Nanostructured lipid carriers and stable emulsions and uses thereof |
| WO2019036761A1 (en) * | 2017-08-23 | 2019-02-28 | Griffith University | IMMUNOGENIC PEPTIDE DIRECTED AGAINST GROUP A STREPTOCOCCUS |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| US12291717B2 (en) | 2017-09-13 | 2025-05-06 | Biontech Rna Pharmaceuticals Gmbh | RNA replicon for reprogramming somatic cells |
| AU2018333530B2 (en) | 2017-09-13 | 2024-05-30 | Biontech Cell & Gene Therapies Gmbh | RNA replicon for expressing a T cell receptor or an artificial T cell receptor |
| EP3681514A4 (en) | 2017-09-14 | 2021-07-14 | ModernaTX, Inc. | RNA VACZINE AGAINST ZIKA VIRUS |
| EP3461497A1 (en) | 2017-09-27 | 2019-04-03 | GlaxoSmithKline Biologicals S.A. | Viral antigens |
| JP7354106B2 (ja) * | 2017-12-04 | 2023-10-02 | インターベット インターナショナル ベー． フェー． | レプリコン粒子および油性アジュバントによるワクチン接種 |
| US11883476B2 (en) | 2017-12-04 | 2024-01-30 | Intervet Inc. | Canine lyme disease vaccine |
| AU2019321186B2 (en) * | 2018-08-17 | 2024-05-23 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
| EP3853202A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| CN112996854B (zh) | 2018-09-19 | 2024-08-30 | 摩登纳特斯有限公司 | 高纯度peg脂质和其用途 |
| US12151029B2 (en) | 2018-09-19 | 2024-11-26 | Modernatx, Inc. | PEG lipids and uses thereof |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| WO2020144295A1 (en) | 2019-01-10 | 2020-07-16 | Biontech Rna Pharmaceuticals Gmbh | Localized administration of rna molecules for therapy |
| CN113939282A (zh) | 2019-01-31 | 2022-01-14 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
| MA55321A (fr) | 2019-03-15 | 2022-01-19 | Modernatx Inc | Vaccins à base d'arn contre le vih |
| MX2022000879A (es) | 2019-07-21 | 2022-05-02 | Glaxosmithkline Biologicals Sa | Vacuna viral terapeutica. |
| AU2020315962B2 (en) * | 2019-07-23 | 2026-02-12 | Translate Bio, Inc. | Stable compositions of mRNA-loaded lipid nanoparticles and processes of making |
| EP4031524A1 (en) | 2019-09-19 | 2022-07-27 | ModernaTX, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| AU2020351220A1 (en) | 2019-09-19 | 2022-04-07 | Modernatx, Inc. | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents |
| US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
| WO2021194672A1 (en) | 2020-03-23 | 2021-09-30 | Hdt Bio Corp. | Compositions and methods for delivery of rna |
| JP2022552552A (ja) * | 2019-10-16 | 2022-12-16 | イムノバクシーン・テクノロジーズ・インコーポレイテッド | 活性薬剤または治療剤の送達のための水中油型エマルジョン製剤 |
| EP3819377A1 (en) | 2019-11-08 | 2021-05-12 | Justus-Liebig-Universität Gießen | Circular rna and uses thereof for inhibiting rna-binding proteins |
| US20230364219A1 (en) | 2020-04-16 | 2023-11-16 | Glaxosmithkline Biologicals Sa | Sars cov-2 spike protein construct |
| JP7769644B2 (ja) | 2020-06-04 | 2025-11-13 | バイオエヌテック エスエー | 多用途かつ効率的な遺伝子発現のためのｒｎａレプリコン |
| WO2021245611A1 (en) | 2020-06-05 | 2021-12-09 | Glaxosmithkline Biologicals Sa | Modified betacoronavirus spike proteins |
| EP4171629A1 (en) | 2020-06-29 | 2023-05-03 | GlaxoSmithKline Biologicals S.A. | Adjuvants |
| CN112042928B (zh) * | 2020-08-31 | 2022-06-10 | 华南理工大学 | 一种以多羟基醇作为分子伴侣协同高效制备蛋白基纳米乳液的方法及制得的蛋白基纳米乳液 |
| EP4008785A1 (en) | 2020-12-03 | 2022-06-08 | Justus-Liebig-Universität Gießen | Circular nucleic acids and uses thereof for interfering with genome expression and proliferation of coronaviruses |
| US20240301006A1 (en) | 2020-12-23 | 2024-09-12 | Glaxosmithkline Biologicals Sa | Self-amplifying messenger rna |
| AU2022208435A1 (en) | 2021-01-18 | 2023-08-10 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
| EP4032546A1 (en) | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Therapeutic viral vaccine |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| EP4313152A1 (en) | 2021-03-26 | 2024-02-07 | GlaxoSmithKline Biologicals S.A. | Immunogenic compositions |
| US20240285755A1 (en) | 2021-05-24 | 2024-08-29 | Glaxosmithkline Biologicals Sa | Adjuvants |
| WO2022259191A1 (en) | 2021-06-09 | 2022-12-15 | Glaxosmithkline Biologicals Sa | Release assay for determining potency of self-amplifying rna drug product and methods for using |
| WO2023020994A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020993A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020992A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| JP2024535352A (ja) | 2021-09-22 | 2024-09-30 | エイチディーティー バイオ コーポレーション | Ｓａｒｓ－ｃｏｖ－２ ｒｎａワクチン組成物および使用方法 |
| AU2022352486A1 (en) | 2021-09-22 | 2024-04-11 | Hdt Bio Corp. | Dried nanoparticle compositions |
| WO2023049636A2 (en) | 2021-09-22 | 2023-03-30 | Hdt Bio Corp. | Cancer therapy compositions and uses thereof |
| CA3232658A1 (en) | 2021-09-22 | 2023-03-30 | Steven Gregory REED | Rna vaccines against infectious diseases |
| EP4419708A1 (en) | 2021-10-18 | 2024-08-28 | BioNTech SE | Methods for determining mutations for increasing modified replicable rna function and related compositions and their use |
| US20250236883A1 (en) | 2021-10-18 | 2025-07-24 | BioNTech SE | Modified replicable rna and related compositions and their use |
| CN114277039B (zh) * | 2021-10-25 | 2024-06-21 | 浙江君怡生物科技有限公司 | 呼吸道合胞病毒mRNA疫苗及其制备方法和应用 |
| WO2023213378A1 (en) | 2022-05-02 | 2023-11-09 | BioNTech SE | Replicon compositions and methods of using same for the treatment of diseases |
| WO2024017479A1 (en) | 2022-07-21 | 2024-01-25 | BioNTech SE | Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production |
| WO2024056856A1 (en) | 2022-09-15 | 2024-03-21 | BioNTech SE | Systems and compositions comprising trans-amplifying rna vectors with mirna |
| EP4458968A1 (en) | 2023-05-05 | 2024-11-06 | Justus-Liebig-Universität Gießen | Circular nucleic acids and uses thereof for shaping the cellular proteome |
| WO2025040709A1 (en) | 2023-08-24 | 2025-02-27 | BioNTech SE | Systems and compositions comprising highly active trans-amplifying replicases |
| WO2025051381A1 (en) | 2023-09-08 | 2025-03-13 | BioNTech SE | Methods and compositions for localized expression of administered rna |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA583561A (en) | 1959-09-22 | H. Edgerton William | Therapeutically valuable esters and methods for obtaining the same | |
| US3130012A (en) | 1960-07-08 | 1964-04-21 | Kennecott Copper Corp | Handling of solutions containing selenium values |
| FR1317586A (enExample) | 1961-03-17 | 1963-05-08 | ||
| US3906092A (en) | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| CA1341482C (en) | 1984-10-31 | 2005-05-10 | Paul A. Luciw | Process for preparing fragments of aids-associated retroviruses |
| US4689225A (en) | 1984-11-02 | 1987-08-25 | Institut Merieux | Vaccine for cytomegalovirus |
| US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
| DK341386D0 (da) | 1986-07-18 | 1986-07-18 | Voetman Karin Glassau | Fremgangsmaade og apparat til oprulning af flade dejstykker, f.eks. til roulader |
| ES2053549T3 (es) | 1986-08-11 | 1994-08-01 | Innovata Biomed Ltd | Un proceso para la preparacion de una formulacion farmaceutica apropiada para inhalacion. |
| US5906980A (en) | 1987-07-17 | 1999-05-25 | Hem Research Inc. | Treatment of hepatitis with mismatched dsRNA |
| US5712257A (en) | 1987-08-12 | 1998-01-27 | Hem Research, Inc. | Topically active compositions of mismatched dsRNAs |
| WO1989004669A1 (en) | 1987-11-18 | 1989-06-01 | Chiron Corporation | Nanbv diagnostics and vaccines |
| EP0436537A4 (en) | 1988-01-29 | 1992-04-08 | Chiron Corporation | Recombinant cmv neutralizing proteins |
| US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| HUT54896A (en) | 1989-03-17 | 1991-04-29 | Chiron Corp | Process for producing aquous diagnosticum and vaccine of nanbv |
| WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| KR0185426B1 (ko) | 1991-06-24 | 1999-04-01 | 로버트 피. 블랙버언 | 씨형 간염 바이러스 폴리펩티드 |
| DK0608261T3 (da) | 1991-09-13 | 2003-03-17 | Chiron Corp | Sammensætninger med immunreaktivt hepatitis C virus polypeptid |
| JPH09500013A (ja) | 1993-06-01 | 1997-01-07 | ライフ・テクノロジーズ・インコーポレイテッド | カチオン性脂質による遺伝子免疫 |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US6040295A (en) * | 1995-01-13 | 2000-03-21 | Genemedicine, Inc. | Formulated nucleic acid compositions and methods of administering the same for gene therapy |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
| US6120794A (en) | 1995-09-26 | 2000-09-19 | University Of Pittsburgh | Emulsion and micellar formulations for the delivery of biologically active substances to cells |
| ES2301178T3 (es) | 1996-04-05 | 2008-06-16 | Novartis Vaccines & Diagnostic | Vectores basados en alfavirus recombinantes con inhibicion reducida de la sintesis macromolecular celular. |
| US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| JP2001503735A (ja) | 1996-07-03 | 2001-03-21 | ユニバーシティ オブ ピッツバーグ | 親水性活性試薬のためのエマルジョン処方物 |
| EP0938298B1 (en) | 1996-09-13 | 2002-12-04 | Lipoxen Technologies Limited | Liposome-based composition |
| US6884435B1 (en) | 1997-01-30 | 2005-04-26 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
| ES2195317T3 (es) | 1997-01-30 | 2003-12-01 | Chiron Corp | Uso de microparticulas con antigeno adsorbido para estimular respuestas inmunitarias. |
| WO2000006123A1 (en) | 1998-07-29 | 2000-02-10 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| CA2295740A1 (en) | 1997-07-08 | 1999-01-21 | Chiron Corporation | Use of submicron oil-in-water emulsions with dna vaccines |
| PT1042001E (pt) | 1997-12-16 | 2002-09-30 | Chiron Corp | Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua |
| US6218371B1 (en) | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| US20020142974A1 (en) | 1998-09-11 | 2002-10-03 | Leonard D. Kohn | Immune activation by double-stranded polynucleotides |
| US6770282B1 (en) | 1998-10-23 | 2004-08-03 | Heska Corporation | Cationic lipid-mediated enhancement of nucleic acid immunization of cats |
| WO2000050006A2 (en) | 1999-02-26 | 2000-08-31 | Chiron Corporation | Microemulsions with adsorbed macromoelecules and microparticles |
| AP1891A (en) | 1999-05-06 | 2008-09-23 | The Immune Response Corp | HIV immunogenic compositions and methods. |
| WO2001036599A1 (en) | 1999-11-19 | 2001-05-25 | Chiron Corporation | Microparticle-based transfection and activation of dendritic cells |
| WO2002026212A2 (en) | 2000-09-28 | 2002-04-04 | Chiron Corporation | Microparticle compositions and methods for the manufacture thereof |
| US20030138453A1 (en) | 2000-09-28 | 2003-07-24 | O'hagan Derek | Microparticles for delivery of heterologous nucleic acids |
| WO2002087541A1 (en) | 2001-04-30 | 2002-11-07 | Protiva Biotherapeutics Inc. | Lipid-based formulations for gene transfer |
| AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
| US6861410B1 (en) | 2002-03-21 | 2005-03-01 | Chiron Corporation | Immunological adjuvant compositions |
| CA2487274A1 (en) | 2002-05-06 | 2003-11-13 | Nucleonics Inc. | Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent |
| AU2003302226A1 (en) | 2002-09-24 | 2004-06-30 | University Of Kentucky Research Foundation | Nanoparticle-based vaccine delivery system containing adjuvant |
| WO2004058166A2 (en) | 2002-12-23 | 2004-07-15 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
| CN1882693B (zh) | 2003-09-15 | 2012-08-15 | 普洛体维生物治疗公司 | 聚乙二醇修饰的脂质化合物及其应用 |
| US7303881B2 (en) | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
| JP5331340B2 (ja) | 2004-05-18 | 2013-10-30 | バイカル インコーポレイテッド | インフルエンザウィルスワクチン組成物、及びその使用方法 |
| AU2005259799A1 (en) | 2004-07-02 | 2006-01-12 | Protiva Biotherapeutics, Inc. | Immunostimulatory siRNA molecules and uses therefor |
| US7749520B2 (en) | 2004-07-07 | 2010-07-06 | Statens Serum Institut | Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids |
| BRPI0516974A (pt) | 2004-10-21 | 2008-09-30 | Wyeth Corp | composição imunogênica compreendendo um polipeptìdeo; um método para induzir uma resposta imune contra staphylococcus epidermidis; um método para induzir uma resposta imune contra staphylococcus aureus; um método para a detecção e/ou identificação de staphylococcus epidermidis; um método para a detecção e/ou identificação de anticorpos para staphylococcus epidermidis |
| FR2885813B1 (fr) | 2005-05-19 | 2008-01-11 | Oreal | Vectorisation de dsrna par des particules cationiques et leur utilisation sur modele de peau. |
| ES2385924T3 (es) * | 2006-02-02 | 2012-08-03 | Allergan, Inc. | Inhibidores de la actividad de CXCR4 para su uso en el tratamiento de trastornos oculares |
| CA2649630C (en) | 2006-04-20 | 2016-04-05 | Silence Therapeutics Ag | Lipoplex formulations for specific delivery to vascular endothelium |
| US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
| AU2009236306B2 (en) | 2008-04-17 | 2015-04-02 | Pds Biotechnology Corporation | Stimulation of an immune response by enantiomers of cationic lipids |
| JP5781929B2 (ja) | 2008-07-15 | 2015-09-24 | ノバルティス アーゲー | 免疫原性の両親媒性ペプチド組成物 |
| EP2451475A2 (en) * | 2009-07-06 | 2012-05-16 | Novartis AG | Self replicating rna molecules and uses thereof |
| WO2011076807A2 (en) | 2009-12-23 | 2011-06-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| JP5704163B2 (ja) | 2010-03-12 | 2015-04-22 | コニカミノルタ株式会社 | 分子間相互作用の検出方法およびその検出装置 |
| FI4005592T3 (fi) | 2010-07-06 | 2023-01-13 | Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille | |
| CA2804591C (en) | 2010-07-06 | 2019-01-22 | Novartis Ag | Cationic oil-in-water emulsions |
| PT3243526T (pt) * | 2010-07-06 | 2020-03-04 | Glaxosmithkline Biologicals Sa | Distribuição de arn para despoletar múltiplas vias imunitárias |
| US9636410B2 (en) | 2011-07-06 | 2017-05-02 | Glaxosmithkline Biologicals Sa | Cationic oil-in-water emulsions |
| US9655845B2 (en) | 2011-07-06 | 2017-05-23 | Glaxosmithkline Biologicals, S.A. | Oil-in-water emulsions that contain nucleic acids |
| JP6136343B2 (ja) | 2012-06-12 | 2017-05-31 | 株式会社リコー | 情報処理システム、情報処理方法、プログラム、及び記録媒体 |
-
2012
- 2012-07-06 US US14/130,880 patent/US9655845B2/en active Active
- 2012-07-06 SG SG10201605512WA patent/SG10201605512WA/en unknown
- 2012-07-06 EP EP12738311.5A patent/EP2729125B1/en active Active
- 2012-07-06 TR TR2018/02662T patent/TR201802662T4/tr unknown
- 2012-07-06 AU AU2012280901A patent/AU2012280901B2/en not_active Ceased
- 2012-07-06 EP EP17206566.6A patent/EP3424495A1/en not_active Withdrawn
- 2012-07-06 ES ES12738311.5T patent/ES2657547T3/es active Active
- 2012-07-06 RU RU2014104092A patent/RU2606846C2/ru active
- 2012-07-06 CN CN201280043221.6A patent/CN103781470A/zh active Pending
- 2012-07-06 CA CA2840913A patent/CA2840913C/en active Active
- 2012-07-06 JP JP2014519087A patent/JP6059220B2/ja not_active Expired - Fee Related
- 2012-07-06 WO PCT/US2012/045840 patent/WO2013006834A1/en not_active Ceased
- 2012-07-06 MX MX2014000047A patent/MX350198B/es active IP Right Grant
-
2016
- 2016-12-08 JP JP2016238363A patent/JP2017057213A/ja not_active Withdrawn
-
2017
- 2017-01-31 AU AU2017200640A patent/AU2017200640A1/en not_active Abandoned
- 2017-04-24 US US15/495,066 patent/US10307374B2/en active Active
-
2019
- 2019-05-02 US US16/401,452 patent/US11026890B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013531680A5 (enExample) | ||
| RU2014104092A (ru) | Эмульсии типа "масло в воде", которые содержат нуклеиновые кислоты | |
| JP2020524143A5 (enExample) | ||
| JP2014522841A5 (enExample) | ||
| AU2022204146B2 (en) | Biodegradable lipids for the delivery of active agents | |
| Koynova et al. | Hydrophobic moiety of cationic lipids strongly modulates their transfection activity | |
| RU2013104870A (ru) | Катионные эмульсии " масло-в-воде " | |
| Perez et al. | Poly (lactic acid)-poly (ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA | |
| JP6592458B2 (ja) | カチオン性脂質 | |
| Al-Deen et al. | Superparamagnetic nanoparticles for effective delivery of malaria DNA vaccine | |
| Mochizuki et al. | The role of the helper lipid dioleoylphosphatidylethanolamine (DOPE) for DNA transfection cooperating with a cationic lipid bearing ethylenediamine | |
| KR20220156933A (ko) | Rna의 전달을 위한 조성물 및 방법 | |
| JP6077509B2 (ja) | 改良されたアミノ脂質および核酸の送達方法 | |
| RU2014104094A (ru) | Катионные эмульсии масло-в-воде | |
| Lu et al. | Mechanism of pH-sensitive amphiphilic endosomal escape of ionizable lipid nanoparticles for cytosolic nucleic acid delivery: Lu and Sun | |
| US10300150B2 (en) | Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells | |
| JP2026012402A (ja) | 薬物送達のための脂質及び脂質ナノ粒子製剤 | |
| JP2018519818A5 (enExample) | ||
| JP2017536092A5 (enExample) | ||
| JP2017165748A5 (enExample) | ||
| Walsh et al. | Synthesis and characterization of novel zwitterionic lipids with pH-responsive biophysical properties | |
| JP2019519568A5 (enExample) | ||
| JP2010505899A (ja) | 両性リポソームにおけるまたは両性リポソームに関する改善、両性リポソームを処方する方法および両性リポソームに充填する方法 | |
| JP2014522842A5 (enExample) | ||
| JP2015525209A5 (enExample) |